N-glycoside Patents (Class 514/42)
  • Patent number: 10329264
    Abstract: This invention relates to a novel chemical process for the synthesis of N?-benzyl-5-methylisoxazole-3-carbohydrazide (Isocarboxazid) which comprises reacting 5-methyl-3-isoxazole carboxylic acid ester with benzylhydrazine or a salt thereof in an aprotic organic solvent and in the presence of an organic base.
    Type: Grant
    Filed: July 27, 2016
    Date of Patent: June 25, 2019
    Assignee: Lundbeck Pharmaceuticals Italy S.P.A.
    Inventors: Carla De Faveri, Florian Anton Martin Huber, Nicola Antolini
  • Patent number: 10294521
    Abstract: The present disclosure provides a measurement method of telomerase activity with no occurrence of false-negative and high quantitative capability. In the measurement method of telomerase activity of the present disclosure, a solution containing telomerase as a sample solution is mixed with a solution containing primer DNA as a substrate for telomerase even as or after a solution containing non-primer DNA not as a substrate for telomerase is mixed therewith. Non-primer DNA can remove an effect of DNase in the sample solution and prevent occurrence of false-negative. Subsequently, the primer DNA is extended with the telomerase and the extended primer DNA is detected, through which telomerase activity is measured.
    Type: Grant
    Filed: June 18, 2015
    Date of Patent: May 21, 2019
    Assignee: Panasonic Corporation
    Inventors: Hidenobu Yaku, Daisuke Miyoshi
  • Patent number: 10105387
    Abstract: Provided are a temperature sensitive adhesion prevention composition and a method for producing the same, the composition comprising a polyethylene oxide (PEO) containing copolymer, a carboxy polysaccharide, and a monovalent cation.
    Type: Grant
    Filed: July 24, 2014
    Date of Patent: October 23, 2018
    Assignee: Medytox Inc.
    Inventors: Hyun Ho Jung, Gi Hyeok Yang, Chang Hoon Rhee, Cheon Soo Lim
  • Patent number: 10000521
    Abstract: In one aspect, the invention relates to substituted gemcitabine aryl amide analogs, derivatives thereof, and related compounds; synthesis methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of treating viral disorders and disorders of uncontrolled cellular proliferation using the compounds and compositions.
    Type: Grant
    Filed: March 15, 2014
    Date of Patent: June 19, 2018
    Assignee: Nucorion Pharmaceuticals, Inc.
    Inventors: Zucai Suo, Vinod P. Vyavhare, David J. Taggart
  • Patent number: 9963480
    Abstract: A novel nucleoside phosphoramidate compound of the formula below, or a stereoisomer, salt, hydrate, solvate or crystal thereof for the treatment of Flaviviridae family viral infection, especially hepatitis C viral infection, and having a good anti-HCV effect; a pharmaceutical composition having the compound, or a stereoisomer, salt, hydrate, solvate or crystal thereof:
    Type: Grant
    Filed: March 6, 2014
    Date of Patent: May 8, 2018
    Assignee: NANJING SANHOME PHARMACEUTICAL CO., LTD.
    Inventors: Yong Wang, Liwen Zhao, Xian Zhang, Sheng Bi, Yiping Gao, Hongyan Chen, Dezhong Wang, Yang Nan, Cang Zhang, Yuxiu Li, Di Zhang
  • Patent number: 9950989
    Abstract: Provided is a novel compound having an excellent suppression effect against arrhythmia including atrial fibrillation and being useful as a pharmaceutical product without antiviral effect. Disclosed is a compound represented by the following General Formula (I), a pharmaceutically acceptable salt thereof, or a solvate thereof (in the formula, the dotted line portion represents a single bond or a double bond; R1 represents an optionally substituted C1-6 alkyl group; Q represents an oxygen atom, a sulfur atom, or NR5; R2 represents —(C?O)—R6, —CHR6R7, or —CH2OR8; and R3 and R4, which may be identical or different, each represent an amino group, an azide group, or —X—R9, with the proviso that any one of R3 and R4 is an amino group).
    Type: Grant
    Filed: February 13, 2015
    Date of Patent: April 24, 2018
    Assignee: TOA EIYO LTD.
    Inventors: Hidekazu Masaki, Masayuki Kageyama
  • Patent number: 9943604
    Abstract: Provided herein are compounds comprising one or more therapeutic nucleosides and one or more targeting groups. In certain embodiments, the compounds further comprise one or more oligonucleotides. In certain embodiments, a targeting group comprises one or more N-Acetylgalactosamine.
    Type: Grant
    Filed: September 19, 2014
    Date of Patent: April 17, 2018
    Assignee: Ionis Pharmaceuticals, Inc.
    Inventors: Punit P. Seth, Thazha P. Prakash
  • Patent number: 9884886
    Abstract: The present invention relates to disulfide masked prodrug compounds of formula I, compositions and methods that are amenable to bioactivation by a reducing agent such as glutathione: W—P(V)LG??(Formula I), wherein P(V)LG is a pentavalent phosphorus leaving group; and W is: wherein R1, R2, R3, R4, R5, R6, R7 and R8 are as defined in the specification. Such disulfide based compounds, compositions, and methods can be useful, for example, in providing novel prodrugs for use as therapeutics. Once administered, the prodrug is metabolized in vivo into an active metabolite in a process termed bioactivation.
    Type: Grant
    Filed: December 2, 2013
    Date of Patent: February 6, 2018
    Assignee: Merck Sharp & Dohme
    Inventor: Gabor Butora
  • Patent number: 9857381
    Abstract: The present invention relates to a reliable method of prediction of sepsis in humans after a trauma, wherein the level of pancreatic stone protein/regenerating protein (PSP/reg) is determined in serum, and a high level is indicative of the development of sepsis at early stages of the disease. Furthermore a method of determination of PSP/reg levels in serum is described.
    Type: Grant
    Filed: March 29, 2013
    Date of Patent: January 2, 2018
    Assignee: UNIVERSITAET ZUERICH
    Inventors: Rolf Graf, Daniel Bimmler, Marius Keel
  • Patent number: 9827260
    Abstract: There is provided a composition comprising an aminoalkyl glucosaminide phosphate compound or a pharmaceutically salt thereof and a buffer for use as an immunomodulator.
    Type: Grant
    Filed: March 13, 2014
    Date of Patent: November 28, 2017
    Assignee: GLAXOSMITHKLINE BIOLOGICALS SA
    Inventors: David Johnson, David Burkhart, Nupur Dutta
  • Patent number: 9802975
    Abstract: The present disclosure provides nucleoside compounds and oligonucleotides including an unnatural 6-amino-2-pyridone heterocyclic base where the 6-amino and 2-positions are protected. The 2-position of the heterocyclic base can be protected with an acyl-oxy-methyl protecting group. In some embodiments, the protected heterocyclic base has the following structure where AcOM is an acetyl-oxy-methyl group and R is a ribose or deoxyribose sugar: Methods for synthesizing an oligonucleotide are provided in which the subject compounds find use. The method can include protecting an unnatural (e.g., Z) nucleotide with an acetyl-oxy-methyl group; incorporating the protected unnatural nucleotide into a nucleotide sequence on a solid support; and removing the acetyl-oxy-methyl group from the unnatural nucleotide incorporated into the nucleotide sequence. The compounds and methods find use in the synthesis of long oligonucleotides including Z nucleotides.
    Type: Grant
    Filed: May 28, 2015
    Date of Patent: October 31, 2017
    Assignee: Agilent Technologies, Inc.
    Inventors: Benjamin D. Lunstad, Douglas J. Dellinger
  • Patent number: 9789163
    Abstract: The present invention relates to methods for producing N-terminal derivatives of proteins in which a polysaccharide, preferably having at least terminal sialic units, and preferably consisting essentially only of sialic acid units, is reacted at the N-terminus of a protein or peptide under controlled conditions to produce an N-terminal derivative. The controlled conditions include use of acidic pH for the derivatization step and a higher pH for purification. The derivatives are useful for improving pharmacokinetics and pharmacodynamics of proteins and peptides.
    Type: Grant
    Filed: November 15, 2016
    Date of Patent: October 17, 2017
    Assignee: Lipoxen Technologies Limited
    Inventors: Sanjay Jain, Peter Laing, Gregory Gregoriadis
  • Patent number: 9675545
    Abstract: An acicular body includes a support base, and a needle formed on the support base and containing a chitosan derivative.
    Type: Grant
    Filed: December 4, 2015
    Date of Patent: June 13, 2017
    Assignee: TOPPAN PRINTING CO., LTD.
    Inventor: Hiroyuki Kato
  • Patent number: 9669048
    Abstract: Described herein are ready to use, non-aqueous pharmaceutical compositions comprising 5-aza-2?-deoxycitidine and at least one aprotic solvent. The pharmaceutical compositions may further comprise at least one protic solvent. Also described are processes for preparing the pharmaceutical compositions and their use for the treatment of patients suffering from myelodysplastic syndromes.
    Type: Grant
    Filed: October 24, 2013
    Date of Patent: June 6, 2017
    Assignee: Fresenius Kabi Oncology Limited
    Inventors: Dhiraj Khattar, Rajesh Khanna, Sanjay Motwani, Sunny Chopra, Minakshi Garg
  • Patent number: 9657086
    Abstract: Provided are whole egg protein peptides and the preparation method thereof, wherein the whole egg protein peptides are obtained by adopting compound proteases composed of pawpaw protease, fig protease and pineapple protease to enzymatically hydrolyze the whole egg protein powder. The whole egg protein peptides can be used for manufacture of products for enhancing immunity.
    Type: Grant
    Filed: August 24, 2010
    Date of Patent: May 23, 2017
    Assignee: WUHAN JIUSHENGTANG BIOENGINEERING CO., LTD
    Inventor: Yuandong Zou
  • Patent number: 9636434
    Abstract: Ionically cross-linked compositions containing carboxypolysaccharides, polyalkylene oxides, polyhydroxyl organic anions, optionally divalent cations, and aqueous media are provided. Methods for manufacturing ionically cross-linked compositions of carboxypolysaccharides, polyalkylene oxides, polyhydroxyl organic anions, optionally divalent cations, and aqueous media are also provided. Such compositions can be used by placing then in proximity to a tissue in need of lubrication or for prevention of adhesions and adhesion reformation.
    Type: Grant
    Filed: July 21, 2016
    Date of Patent: May 2, 2017
    Assignee: FZIOMED, Inc.
    Inventor: Sasmuel J. Falcone
  • Patent number: 9517219
    Abstract: Dapsone and dapsone/adapalene compositions can be useful for treating a variety of dermatological conditions. The compositions of this disclosure include dapsone and/or adapalene in a polymeric viscosity builder. Subject compositions can be adjusted to optimize the dermal delivery profile of dapsone to effectively treat dermatological conditions and improve the efficiency of pharmaceutical products applied to the skin. Use of the polymeric viscosity builder provides compositions with increased concentrations of diethylene glycol monoethyl ether relative to compositions without the polymeric viscosity builder.
    Type: Grant
    Filed: October 16, 2015
    Date of Patent: December 13, 2016
    Assignee: Allergan, Inc.
    Inventors: Kevin S. Warner, Ajay P. Parashar, Vijaya Swaminathan, Varsha Bhatt
  • Patent number: 9493482
    Abstract: Disclosed herein are compounds, and pharmaceutical compositions that include such compounds, for preventing or treating hearing loss. The compounds and pharmaceutical compositions described herein prevent or treat hair cell death. In addition, the compounds and pharmaceutical compositions described herein protect against kidney damage in an individual receiving an aminoglycoside antibiotic. Methods of using the compounds, alone or in combination with other therapeutic agents, are also disclosed.
    Type: Grant
    Filed: February 5, 2016
    Date of Patent: November 15, 2016
    Assignees: University of Washington, Oricula Therapeutics LLC, Fred Hutchinson Cancer Research Center
    Inventors: Julian Simon, Graham Johnson, Edwin Rubel, David Raible, Mario D. Gonzalez, Peter C. Meltzer, Weishi Miao
  • Patent number: 9415065
    Abstract: Methods of mitigating the effects of radiation exposure or providing a radioprotective effect in a subject are provided herein. The methods include administering a therapeutically effective amount of cerium oxide nanoparticles to the subject to mitigate the effects of radiation exposure or to offer a radioprotective effect to the subject. The cerium oxide nanoparticles are suitably less than 20 nm in diameter and have over 50% of the cerium in the 3+ oxidation state.
    Type: Grant
    Filed: March 13, 2013
    Date of Patent: August 16, 2016
    Assignees: UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC., DUKE UNIVERSITY
    Inventors: Zeljko Vujaskovic, Isabel L. Jackson, Sudipta Seal, Soumen Das
  • Patent number: 9387170
    Abstract: A liposome containing a regulatory cell ligand such as ?-galactosyl ceramide or ?-galactosyl ceramide is employed as the active ingredient of a drug for preventing or treating immune diseases etc.
    Type: Grant
    Filed: November 13, 2014
    Date of Patent: July 12, 2016
    Assignee: RIKEN
    Inventors: Yasuyuki Ishii, Risa Nozawa, Masaru Taniguchi
  • Patent number: 9241896
    Abstract: Extended release formulations, methods of making, and methods of use, for example, in treatment of sialic acid deficiencies.
    Type: Grant
    Filed: October 24, 2012
    Date of Patent: January 26, 2016
    Assignee: ULTRAGENYX PHARMACEUTICAL INC.
    Inventor: Emil Kakkis
  • Patent number: 9061041
    Abstract: The present invention relates to 2?-Substituted Nucleoside Derivatives of Formula (I): and pharmaceutically acceptable salts thereof, wherein A, B, X, R1, R2 and R3 are as defined herein. The present invention also relates to compositions comprising at least one 2?-Substituted Nucleoside Derivative, and methods of using the 2?-Substituted Nucleoside Derivatives for treating or preventing HCV infection in a patient.
    Type: Grant
    Filed: April 11, 2012
    Date of Patent: June 23, 2015
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Vinay Girijavallabhan, F. George Njoroge, Stephane Bogen, Vishal Verma, Frank Bennett, Angela Kerekes, Ashok Arasappan, Dmitri Pissarnitski, Qun Dang, Ian Davies, David B. Olsen, Andrew Stamford, Joseph P. Vacca
  • Patent number: 9040498
    Abstract: The present invention relates to novel 1,2,3-triazolyl purine derivatives. The invention also relates to using the derivatives to treat cancer and various viral infections.
    Type: Grant
    Filed: July 8, 2013
    Date of Patent: May 26, 2015
    Assignee: Research Foundation of the City University of New York
    Inventor: Mahesh K. Lakshman
  • Patent number: 9029345
    Abstract: An agent for inhibiting P-glycoproteins comprises a non-natural adenine ribose analog.
    Type: Grant
    Filed: November 16, 2007
    Date of Patent: May 12, 2015
    Assignee: Case Western Reserve University
    Inventors: Anthony J. Berdis, Irene Lee
  • Patent number: 9029335
    Abstract: Provided herein are novel bicyclic nucleosides, oligomeric compounds that include such bicyclic nucleosides and methods of using the oligomeric compounds. More particularly, the novel bicyclic nucleosides comprise a furanose ring system having a bridge comprising a 4?-methylene group attached to a 2?-sulfoxide or sulfone group and optionally including one or more substituent groups attached to the 4?-methylene and or the 5?-position. In certain embodiments, the oligomeric compounds provided herein are expected to hybridize to a portion of a target RNA resulting in loss of normal function of the target RNA.
    Type: Grant
    Filed: October 9, 2013
    Date of Patent: May 12, 2015
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Thazha P. Prakash, Eric E. Swayze
  • Patent number: 9029346
    Abstract: Methods and compounds are disclosed for irreversibly inhibiting a DNA repair enzyme that possesses lyase activity.
    Type: Grant
    Filed: December 13, 2013
    Date of Patent: May 12, 2015
    Assignee: The Johns Hopkins University
    Inventors: Marc M. Greenberg, Dumitru Arian, Theodore L. Deweese, Mohammad Hedayati
  • Publication number: 20150125410
    Abstract: A hyaluronic acid production promoter and a melanin synthesis inhibitor include soybean saponin as an active ingredient. The soybean saponin can be a soybean saponin aglycone, such as soyasapogenol A and/or soyasapogenol B. The hyaluronic acid production promoter and melanin synthesis inhibitor can be administered transdermally or orally.
    Type: Application
    Filed: January 9, 2015
    Publication date: May 7, 2015
    Inventors: Shuichi KAMO, Shunsuke SUZUKI, Toshiro SATO
  • Patent number: 9023818
    Abstract: Hydrophilic N-linked pharmaceutical compositions, methods of their preparation and use in neuraxial drug delivery comprising a glycosyl CNS acting prodrug compound covalently N-linked with a saccharide through an amide or an amine bond and a formulary consisting of an additive, a stabilizer, a carrier, a binder, a buffer, an excipient, an emollient, a disintegrant, a lubricating agent, an antimicrobial agent or a preservative, with the proviso that the saccharide moiety is not a cyclodextrin or a glucuronide.
    Type: Grant
    Filed: October 27, 2010
    Date of Patent: May 5, 2015
    Assignee: Glycon LLC
    Inventor: Samuel T. Christian
  • Patent number: 9012410
    Abstract: A method of treating intrauterine inflammation in a subject associated with intrauterine bacterial infection includes administering to the subject a therapeutically effective amount of a toll-like receptor 4 antagonist. The therapeutically effective amount administered to the subject is an amount effective in reducing intrauterine inflammation in the subject.
    Type: Grant
    Filed: December 13, 2007
    Date of Patent: April 21, 2015
    Assignee: Case Western Reserve University
    Inventors: Yiping Han, Hongqi Liu
  • Patent number: 9012416
    Abstract: This invention provides a pharmaceutical solution formulation comprising tobramycin, water, sodium chloride and sodium citrate, wherein the formulation has a pH of 4.5-7.0 and an osmolality of 135-200 mOsmol/Kg.
    Type: Grant
    Filed: March 19, 2013
    Date of Patent: April 21, 2015
    Assignee: Norton Healthcare Limited
    Inventors: Kevin Hawkins, David Higham
  • Patent number: 9012427
    Abstract: Disclosed herein are pharmaceutical compositions that can include a thionucleotide analog for use in combination therapy with other agents. Also disclosed herein are methods of treating diseases and/or conditions with a pharmaceutical composition that can include a thionucleotide analog in combination therapy with other agents.
    Type: Grant
    Filed: March 12, 2013
    Date of Patent: April 21, 2015
    Assignee: Alios BioPharma, Inc.
    Inventors: Lawrence M Blatt, Leonid Beigelman, Hua Tan, Julian Alexander Symons, David Bernard Smith, Min Jiang, Tara Lynn Kieffer, Cornelis Arie Rijnbrand
  • Patent number: 8993527
    Abstract: The present invention provides methods, compositions, formulations, and kits related to acadesine, or a prodrug, analog, or salt thereof, and/or a blood clotting inhibitor for preventing or reducing adverse side effects in a patient. The type of patient that may benefit includes a patient with decreased left ventricular function, a patient with a prior myocardial infarction, a patient undergoing non-vascular surgery, or a fetus during labor and delivery.
    Type: Grant
    Filed: March 28, 2006
    Date of Patent: March 31, 2015
    Assignee: Pericor Therapeutics, Inc.
    Inventor: Dennis T. Mangano
  • Patent number: 8993528
    Abstract: The present disclosure provides tricyclic nucleosides, oligomeric compounds comprising at least one of the tricyclic nucleosides and methods of using the oligomeric compounds. The methods provided herein include contacting a cell or administering to an animal at least one of the oligomeric compounds. In certain embodiments, the oligomeric compounds hybridize to a portion of a target RNA resulting in loss of normal function of the target RNA.
    Type: Grant
    Filed: March 21, 2013
    Date of Patent: March 31, 2015
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Eric E. Swayze, Andrew M. Siwkowski, Punit P. Seth, Thazha P. Prakash
  • Publication number: 20150086631
    Abstract: Chitosan nanoparticles are provided for use in the in vivo treatment of connective tissues in root canal therapies. The nanoparticles are optionally linked with one or more photoactivatable compounds for providing antibactenal/antibiofilm properties, neutralizing bacterial byproducts and/or chemical/photodynamic crosslinking to achieve enhanced mechanical properties, chemical stability in connective tissues and/or to improve surface/interfacial integrity between filling material and connective tissue.
    Type: Application
    Filed: March 21, 2013
    Publication date: March 26, 2015
    Applicant: THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO
    Inventors: Anil Kishen, Annie Shrestha
  • Patent number: 8987304
    Abstract: The present invention provides antituberculous therapeutic drugs with a higher potency. The present invention provides also antituberculous therapeutic drugs containing oxazole compounds represented by (I) general formula (1): [wherein R1 represents a hydrogen atom or C1-6 alkyl group, n represents an integer of 0-6, and R2 represents general formula (A) or the like, wherein R3 represents a phenoxy group (at least one group selected from the group consisting of a halogen atom, an optionally halogen-substituted C1-6 alkyl group and an optionally halogen-substituted C1-6 alkoxy group may be substituted on the phenyl ring) or the like], optically active forms thereof or salts thereof, and drugs (II) such as primary antituberculous drugs.
    Type: Grant
    Filed: October 4, 2006
    Date of Patent: March 24, 2015
    Assignee: Otsuka Pharmaceutical Co., Ltd.
    Inventors: Makoto Matsumoto, Hiroyuki Hashizume, Tatsuo Tomishige, Masanori Kawasaki, Yoshihiko Shimokawa
  • Publication number: 20150079055
    Abstract: An individual at risk for necrotizing enterocolitis and related disorders can be identified by measuring the level of at least one secretor antigen in a biological sample from the individual and comparing the measured level of the at least one secretor antigen to a predetermined value or a predetermined range of values. Among the secretor antigens which can be measured are: the H-1, H-2, Lewisb and Lewisy antigens and derivatives thereof (e.g., a sialylated form of Lewis a, Lewis x, Lewis b, Lewis y; H-1, H-2, Lewis a, Lewis x, Lewis b or Lewis y).
    Type: Application
    Filed: September 23, 2014
    Publication date: March 19, 2015
    Applicants: Children's Hospital Medical Center, The General Hospital Corporation, Instituto Nacional de Ciencias Medicas Y Nutricion
    Inventors: Ardythe L. Morrow, David S. Newburg, Guillermo M. Ruiz-Palacios
  • Patent number: 8980228
    Abstract: The present invention relates, e.g., to a system for treating damaged skin, comprising a cosmeceutical formulation comprising about 1-10% of a mixture of perfluorocarbons (PFC's) of at least three different molecular weights, and about 0.001-5% hyaluronic acid (HA) of molecular weight about 100 kDa or less, packaged in an aerosol spray container.
    Type: Grant
    Filed: March 4, 2013
    Date of Patent: March 17, 2015
    Assignee: Kate Somerville Skincare, LLC
    Inventors: Kate Somerville, Fred Khoury
  • Patent number: 8980850
    Abstract: The present disclosure relates to methods for the treatment of cancer in patients in recognized need of such treatment. The methods comprise administering to such a patient an NAE inhibitor or a pharmaceutically acceptable salt thereof, such as ((1S,2S,4R)-4-(4-((1S)-2,3-dihydro-1H-inden-1-ylamino)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-2-hydroxycyclopentyl)methyl sulfamate (MLN4924) or {(1S,2S,4R)-4-[(6-{[(1R,2S)-5-chloro-2-methoxy-2,3-dihydro-1H-inden-1-yl]amino}pyrimidin-4-yl)oxy]-2-hydroxycyclopentyl}methyl sulfamate (I-216), and a hypomethylating agent or a pharmaceutically acceptable salt thereof, such as azacitidine or decitabine. Also disclosed are medicaments for use in the treatment of cancer.
    Type: Grant
    Filed: November 2, 2012
    Date of Patent: March 17, 2015
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventor: Peter G. Smith
  • Patent number: 8980227
    Abstract: The present invention relates, e.g., to a system for treating damaged skin, comprising a cosmeceutical formulation comprising about 1-10% of a mixture of perfluorocarbons (PFC's) of at least three different molecular weights, and about 0.001-5% hyaluronic acid (HA) of molecular weight about 100 kDa or less, packaged in an aerosol spray container.
    Type: Grant
    Filed: August 16, 2012
    Date of Patent: March 17, 2015
    Assignee: Kate Somerville Skincare, LLC
    Inventors: Kate Somerville, Fred Khoury
  • Patent number: 8975239
    Abstract: A first aspect of the invention relates to a combination comprising a DNA methyltransferase inhibitor and 1-(2-C-cyano-2-dioxy-?-D-arabino-pentofuranosyl)-N4-palmitoyl cytosine, or a metabolite thereof. A second aspect of the invention relates to a pharmaceutical product comprising a DNA methyltransferase inhibitor and 1-(2-C-cyano-2-dioxy-?-D-arabino-pentofuranosyl)-N4-palmitoyl cytosine, or a metabolite thereof, as a combined preparation for simultaneous, sequential or separate use in therapy. A third aspect of the invention relates to a method of treating a proliferative disorder, said method comprising simultaneously, sequentially or separately administering a DNA methyltransferase inhibitor and 1-(2-C-cyano-2-dioxy-?-D-arabino-pentofuranosyl)-N4-palmitoyl cytosine, or a metabolite thereof, to a subject.
    Type: Grant
    Filed: August 6, 2013
    Date of Patent: March 10, 2015
    Assignee: Cyclacel Limited
    Inventors: Simon Richard Green, Ruth Mackay, Ian Neil Fleming
  • Patent number: 8968709
    Abstract: Dental compositions are provided comprising a compound of Formula (I) or a pharmaceutically acceptable salt thereof: wherein n is an integer from about 2 to about 5.
    Type: Grant
    Filed: July 10, 2008
    Date of Patent: March 3, 2015
    Assignee: 3M Innovative Properties Company
    Inventors: Jie Yang, Bhaskar V. Velamakanni, Sumita B Mitra, Alphonsus V. Pocius, John J. Stofko, Jr., Jeremy M. Yarwood
  • Publication number: 20150051165
    Abstract: The present invention discloses an application of depolymerized holothurian glycosaminoglycans (DHG) in preparation of a drug for the prevention and treatment of thromboembolic diseases. The DHG is more than one type of DHG with weight-average molecular weights between 26,000 and 45,000 Da. When being intravenously or subcutaneously injected, the drug using the DHG with weight-average molecular weights between 26,000 and 45,000 Da as an active ingredient has a significant anticoagulant effect, while at the same time, has little side effects, and is effective for use in the prevention and treatment of the thromboembolic diseases. For an injection of DHG with weight-average molecular weights between 26,000 Da and 45,000 Da, the blood coagulation time is prolonged and the anticoagulant effect is enhanced as the dosage increases; the subcutaneous administration is used and is more favorable for use in the drug, and the convenience and safety of use the drug are improved.
    Type: Application
    Filed: March 1, 2013
    Publication date: February 19, 2015
    Applicants: Shanghai Kairun Biology Medicine Limited Liability Company, Harbin Hongdoushan Bio-Pharm Co., Ltd., Heilongjiang Hongdoushan Pharmaceutical Co., Ltd
    Inventors: Zhiguo Wang, Quanhai Liu, Xuehai Wu
  • Patent number: 8957046
    Abstract: Disclosed herein are phosphoramidate prodrugs of nucleoside derivatives for the treatment of viral infections in mammals, which is a compound, its stereoisomer, salt (acid or basic addition salt), hydrate, solvate, or crystalline form thereof, represented by the following structure: Also disclosed are methods of treatment, uses, and processes for preparing each of which utilize the compound represented by formula I.
    Type: Grant
    Filed: April 16, 2014
    Date of Patent: February 17, 2015
    Assignee: Gilead Pharmasset LLC
    Inventors: Jinfa Du, Dhanapalan Nagarathnam, Michael Joseph Sofia, Peiyuan Wang
  • Publication number: 20150005245
    Abstract: Sialic acid derivatives of the formula (I) in which the symbols have the definitions stated in the description are suitable as medicaments, more particularly for diseases whose course is influenced by Siglec ligands.
    Type: Application
    Filed: December 21, 2012
    Publication date: January 1, 2015
    Inventors: Reinhard Brossmer, Horst Prescher
  • Publication number: 20150005232
    Abstract: Disclosed are compounds of Formula 1, and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, R5, and R6 are defined in the specification. This disclosure also relates to materials and methods for preparing compounds of Formula 1, to pharmaceutical compositions which contain them, and to their use for treating obesity and related diseases, disorders, and conditions associated with MetAP2.
    Type: Application
    Filed: February 28, 2013
    Publication date: January 1, 2015
    Applicant: Takeda Pharmaceutical Company Limited
    Inventors: Zacharia Cheruvallath, Philip Erickson, Jun Feng, Mallareddy Komandla, John David Lawson, Christopher McBride, Joanne Miura, Sean Murphy, Mingnam Tang, Huong-Thu Ton-Nu
  • Patent number: 8916536
    Abstract: The present invention relates to novel bisphosphonate duplex drugs, methods for preparing said compound; pharmaceutical compositions containing the same; as well as the use of said compounds in human and veterinary medicine, and, in particular, for treating tumors, viral infections; or dental disorders.
    Type: Grant
    Filed: August 3, 2011
    Date of Patent: December 23, 2014
    Inventor: Herbert Schott
  • Patent number: 8916528
    Abstract: A resveratrol-containing composition capable of providing a therapeutic benefit to a subject such as modulation of a biological activity, improving cell transplantation therapy, or improving macular degeneration or dystrophy treatments. The compositions comprise trans-resveratrol, a metal chelator, one or more additional antioxidants such as quercetin, gamma-tocotrienol, or apple polyphenols, allicin, and nucleotides.
    Type: Grant
    Filed: November 16, 2012
    Date of Patent: December 23, 2014
    Assignee: Resveratrol Partners, LLC
    Inventor: William F. Sardi
  • Patent number: 8906869
    Abstract: The inventors have determined, contrary to the prior art and experience, how to successfully use triciribine to treat ovarian cancer by one or a combination of (i) administering triciribine only to patients which according to a diagnostic test described below, exhibit enhanced sensitivity to the drug; (ii) use of a described dosage level that minimizes the toxicity of the drug but yet still exhibits efficacy; or (iii) use of a described dosage regimen that minimizes the toxicity of the drug. The invention further encompasses a number of miRNAs, which are altered in human ovarian cancer, with the most significantly deregulated miRNAs being miR-214, -199a*, -200a, -100, -12Sb, and let-7 cluster. Further, the invention illustrates that frequent deregulation of miR-214, -199a*, -200a and -100 in ovarian cancers and their alterations are associated with high grade and late stage tumor.
    Type: Grant
    Filed: July 8, 2013
    Date of Patent: December 9, 2014
    Assignee: University of South Florida
    Inventor: Jin Q. Cheng
  • Publication number: 20140357593
    Abstract: The present invention relates to a topical composition for use on skin containing theanine derivatives as active components and, more particularly, to a topical composition for use on skin having anti-aging, skin wrinkle repair, skin barrier enhancement, skin immunity enhancement, skin moisturizing, and atopy alleviation effects by containing theanine derivatives as active components.
    Type: Application
    Filed: November 8, 2012
    Publication date: December 4, 2014
    Applicant: AMOREPACIFIC CORPORATION
    Inventors: Jin Young Lee, Jae Won Yoo, Hyang Tae Choi, Han Byul Kim, Sung Hoon Lee, Ji Seong Kim, Ji Hyun Bae
  • Patent number: 8901080
    Abstract: This invention discloses a new conjugate compound that comprises at least one HA oligomer derivatized through one thiolated linker, whereby it binds to at least one metal nanoparticle, such as, for example, a gold nanoparticle. Moreover, it discloses methods of obtaining it, as well as the use thereof in a cosmetic treatment, and cosmetic compositions that contain them.
    Type: Grant
    Filed: January 5, 2009
    Date of Patent: December 2, 2014
    Assignee: Endor Nanotechnologies, S.L.
    Inventors: Marc Ramis Castelltort, Isaac Ojea Jimenez, Joaquin Querol Sastre